A recent study from the Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; Excellence Cluster REBIRTH, Hannover Medical School, Hannover, Germany; and National Heart and Lung Institute, Imperial College, London, United Kingdom shows that “Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction.” This study was published in the 4 Oct 2016 issue of Journal of the American College of Cardiology (One of the best journals in Cardiology with an impact factor of 17.759) by Prof Thum, Shashi Gupta, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for aged patients with Myocardial Infarction: Berberine, an isoquinoline alkaloid isolated from Phellodendron amurense, and Tinospora cordifolia, induces autophagy in cardiomyocytes, inhibits cardiomyocyte hypertrophy, improves myocardial function in Post myocardial-infarction patients via up-regulation of PPAR-α, PNUTS/PPP1R10 and Sirutin1
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural-product based drug.
This study suggests a natural product-based cardiac therapy for aged and post-Myocardial Infarct (MI) patients. Berberine, by decreasing the expression of its target gene, it may increase the expression of Peroxisome proliferator-activated receptor-α, Sirtuin1, and PNUTS. Thereby, it may: (1) activate cardiac autophagy; (2) inhibit cardiac hypertrophy (decrease cardiomyocyte cell size); (3) inhibit DNA damage responses; (4) inhibit telomere shortening; (5) prevent post-infarction remodelling; (6) promote cardiomyocyte survival/regeneration; (7) improve myocardial function post-MI; and (8) rejuvenate aged myocardium.
Thus, by treating post-MI patients with Berberine, one may rejuvenate aged myocardium; and prevent aging-associated decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Berberine or its analogs“ may be used to prevent cardiac hypertrophy and improve myocardial function in Post-myocardial-infarct paitients.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
To cite: Boominathan,Natural product therapy for aged patients with Myocardial Infarction: Berberine, an isoquinoline alkaloid isolated from Phellodendron amurense, and Tinospora cordifolia, induces autophagy in cardiomyocytes, inhibits cardiomyocyte hypertrophy, improves myocardial function in Post myocardial-infarction patients via up-regulation of PPAR-α, PNUTS/PPP1R10 and Sirutin1, 21/October/2016, 1.31 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
Undisclosed information: How Berberine increases the expression of PPAR-alpha, Sirtuin1 and PNUTS
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Results guaranteed if not refunded
# Research cooperation